Erythropoietin-receptor agonists in critically ill patients: A meta-analysis of randomized controlled trials

CMAJ. Canadian Medical Association Journal

Volumn 177, Issue 7, 2007, Pages 725-734

  Zarychanski, Ryan ^a,b   Turgeon, Alexis F ^c,d   McIntyre, Lauralyn ^a,b   Fergusson, Dean A ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; FOLIC ACID; HEMOGLOBIN; IRON; PLACEBO; ANTIANEMIC AGENT; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; ARTIFICIAL VENTILATION; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; FOLLOW UP; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG EDEMA; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; SENSITIVITY ANALYSIS; STROKE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG POTENTIATION; ERYTHROCYTE TRANSFUSION; RANDOMIZED CONTROLLED TRIAL;

ANEMIA; CRITICAL ILLNESS; EPOETIN ALFA; ERYTHROCYTE TRANSFUSION; HEMATINICS; HUMANS; RECEPTORS, ERYTHROPOIETIN;

EID: 34748925835     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.071055     Document Type: Article

References (25)

1. Corwin HL, Gettinger A, Rodriguez UM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999;27:2346-50.
2. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study: anemia and blood transfusion in the critically ill - current clinical practice in the United States. Crit Care Med 2004;32:39-52.
3. Rodriguez RM, Corwin HL, Gettinger A, et al. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 2001;16:36-41.
4. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002;288:1499-507.
5. Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults. Pattern of use and effect on transfusion requirements. N Engl J Med 1986;314:1233-5.
6. Henry mL, Garner WL, Fabri PJ. Iatrogenic anemia. Am J Surg 1986;151:362-3.
7. Corwin HL, Parsonnet KC, Gettinger A. RBC transfusion in the ICU. Is there a reason? Chest 1995;108:767-71.
8. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002;288:2827-35.
9. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357:965-76.
10. Gabriel A, Kozek S, Chiari A, et al. High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma 1998;44:361-7.
11. Georgopoulos D, Matamis D, Routsi C, et al. Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. Crit Care 2005;9:R508-15.
12. Silver M, Corwin MJ, Bazan A, et al. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial. Crit Care Med 2006;34:2310-6.
13. Still JM Jr, Belcher K, Law EJ, et al. A double-blinded prospective evaluation of recombinant human erythropoietin in acutely burned patients. J Trauma 1995;38:233-6.
14. Van Iperen CE, Gaillard CA, Kraaijenhagen RJ, et al. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000;28:2773-8.
15. Vincent JL, Spapen HD, Creteur J, et al. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial. Crit Care Med 2006;34:1661-7.
16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
17. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
18. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
19. McGinn T, Wyer PC, Newman TB, et al. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). CMAJ 2004;171:1369-73.
20. Chakraborty A, Natarajan J, Guilfoyle M, et al. Population pharmacokinetics of erythropoietin in critically ill subjects. J Clin Pharmacol 2005;45:193-202.
21. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 2007;176:1091-6.
22. Cook D, Crowther M. Targeting anemia with erythropoietin during critical illness. N Engl J Med 2007;357:1037-9.
23. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. [Cochrane review] In: The Cochrane Library; Issue 3, 2006. Oxford: Update Software.
24. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84.
25. Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I: Medical. Stat Med 1989;8:441-54.